ArticleFrontiers in oncology2025
Long-term outcomes and patterns of failure after empiric SBRT for presumed early-stage lung tumors.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stereotactic body radiation therapy (SBRT) is the established standard of care for medically inoperable early-stage non-small cell lung cancer (ES-NSCLC). When a biopsy is unfeasible, it is often delivered empirically, yet long-term outcomes and failure patterns remain underreported. Methods: A total of 56 patients with clinically staged T1-T3N0M0 lung tumors treated with empiric SBRT (2011-2022) were retrospectively analyzed. Nineteen patients with recurrence were assessed for failure patterns and survival. Overall survival (OS), progression-free survival (PFS), local failure-free survival (LFFS), regional failure-free survival (RFFS), and distant metastasis-free survival (DMFS) were estimated using the Kaplan-Meier method. Competing risk analysis was performed with death treated as a competing event. Results: At a median follow-up of 80.4 months (95% CI: 65.2-95.6), 17 patients (30.4%) were alive. Median PFS and OS were 28.5 months (95% CI: 16.4-40.8) and 41.7 months (95% CI: 14.0-69.4), respectively. LFFS was 84.1% at 5 years and 67.3% at 10 years, RFFS was 64.7% at 5 years and 58.8% at 10 years, and DMFS was 62.4% at 5 years and 56.1% at 10 years. Pathologic confirmation of recurrence was obtained in 10 patients, identifying NSCLC in six, small cell lung cancer in three, and urothelial carcinoma in one. Local failures were infrequent and occurred early (median 8.3 months), whereas regional and distant recurrences occurred later (median 13.5 and 22.8 months). At 10 years, the estimated cumulative incidence function was 6.3% for local failure, 14.8% for regional failure, 16.6% for distant failure, and 55.8% for death. Conclusion: Empiric SBRT provides durable local control in presumed early-stage NSCLC, but outcomes are limited by comorbid mortality and systemic progression. These findings emphasize its effectiveness as a local therapy and the need for prolonged surveillance and systemic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.